Evidence map›Paper›PMID 36398414›Full record

ArticleHealth expectations : an international journal of public participation in health care and health policy2023

Stakeholder outcome prioritization in the Biologic Abatement and Capturing Kids' Outcomes and Flare Frequency in Juvenile Spondyloarthritis (BACK-OFF JSpA) trial.

Emily Neu, Cora Sears, Timothy Brandon, Melanie Kohlheim, Jenny Leal, Kweli Archie, English Holland, Miles Holland, Aamena Hameed, Asad Khan and 10 more

Open access · goldAbstract read
In one paragraph

Article in Health expectations : an international journal of public participation in health care and health policy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Stakeholder outcome prioritization in the Biologic Abatement and Capturing Kids' Outcomes and Flare Frequency in Juvenile Spondyloarthritis (BACK-OFF JSpA) trial.Health expectations : an international journal of public participation in health care and health policy · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 1 institution in 1 country.

Emily NeuDepartment of Pediatrics, Division of Rheumatology, Clinical Futures: A CHOP Research Institute Center of Emphasis, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Cora SearsDepartment of Pediatrics, Division of Rheumatology, Clinical Futures: A CHOP Research Institute Center of Emphasis, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.ORCID 0000-0001-5539-2871
Timothy BrandonDepartment of Pediatrics, Division of Rheumatology, Clinical Futures: A CHOP Research Institute Center of Emphasis, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Melanie KohlheimBACK-OFF JSpA Research Partners Group, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Jenny LealBACK-OFF JSpA Research Partners Group, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Kweli ArchieBACK-OFF JSpA Research Partners Group, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
English HollandBACK-OFF JSpA Research Partners Group, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Miles HollandBACK-OFF JSpA Research Partners Group, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Aamena HameedBACK-OFF JSpA Research Partners Group, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Asad KhanBACK-OFF JSpA Research Partners Group, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Lynn MurphyBACK-OFF JSpA Research Partners Group, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Sean MurphyBACK-OFF JSpA Research Partners Group, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Antoinette NeuBACK-OFF JSpA Research Partners Group, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Jerome NeuBACK-OFF JSpA Research Partners Group, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Justin NeuBACK-OFF JSpA Research Partners Group, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Rachel RichmondBACK-OFF JSpA Research Partners Group, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Dylan SupleeBACK-OFF JSpA Research Partners Group, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Theresa SupleeBACK-OFF JSpA Research Partners Group, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Christopher B ForrestBACK-OFF JSpA Research Partners Group, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Pamela F WeissDepartment of Pediatrics, Division of Rheumatology, Clinical Futures: A CHOP Research Institute Center of Emphasis, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Children's Hospital of Philadelphia · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe Biologic Abatement and Capturing Kids' Outcomes and Flare Frequency in Juvenile Spondyloarthritis (BACK-OFF JSpA) study is a randomized, pragmatic trial investigating different tumour necrosis factor inhibitor de-escalation strategies for children with sustained inactive disease. In this project, we elicited concept rankings that aided in the selection of the patient-reported outcome (PRO) measures that should be examined as part of the BACK-OFF JSpA trial.

methodsWe conducted a discrete choice experiment to evaluate individuals' preferences regarding PROs. Stakeholders assessed a discrete list of 21 outcome concepts, each of which had a Patient-Reported Outcome Measurement Information System (PROMIS) measure associated with it. PROMIS measures are self- or proxy-reported instruments that are universally applicable to the general population and all chronic conditions. Stakeholders were required to make choices instead of expressing the strength of a preference.

resultsFourteen caregivers, 12 patients (9-22 years old), 16 rheumatologists and three executives from health insurance companies completed the exercise, which took approximately 10 min. The discrete choice experiment resulted in an estimate of the relative importance of each outcome and rank. All stakeholder groups agreed that the primary PRO should be 'Pain Interference', a measure that evaluates the effect of pain on a child's everyday activities, including its impact on social, emotional, mental and physical functioning. Patients and caregivers were mostly aligned in their top priorities, with patients valuing physical health (50% of the top 10) whereas caregivers were more interested in mental health (60% of the top 10). Rheumatologists and health insurance executives were most interested in physical health outcomes, which were ranked 80% and 60% of their top 10 PROs, respectively. Overall, the patients had the most diverse set of prioritized outcomes, including at least one of each category in their top 10 rank order of importance. Patients were also the only stakeholders to prioritize 'social' health.

conclusionsPatients and caregivers were mostly aligned in their outcome priority rankings. The rank-order list directly informed the creation of a profile of PRO measures for our upcoming trial. PATIENT OR PUBLIC CONTRIBUTION: Stakeholder partners helped with acquisition of data and lead parent partners helped interpret data.

Indexed as

Arthritis, JuvenileBiological ProductsSpondylarthritisAdolescentAdultCaregiversChildChronic DiseaseHumansPainYoung AdultBiological Productspatient-reported outcomesspondyloarthritisstakeholdertrialtumour necrosis factor inhibitors

Identifiers

PMID36398414
PMCPMC9854298
OpenAlexW4309277434

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.